TMDX insider trades: 3,000 options exercised, 3,000 shares sold

Rhea-AI Filing Summary

TransMedics Group, Inc. (TMDX) reported an insider equity transaction by its Senior Vice President, General Counsel and Secretary. On 11/25/2025, the officer exercised a stock option for 3,000 shares of common stock at an exercise price of $93.88 per share and then sold 3,000 shares of common stock at a weighted average price of $145.22 per share. After these transactions, the officer beneficially owned 13,955 shares of TransMedics common stock directly and held 7,420 stock options directly. The option referenced vested 25% on June 5, 2024 and will continue to vest in equal monthly installments over three years thereafter, subject to continued service.

Insider Trade Summary

Net Seller: 3,000 shares ($435,660)

Net Sell 3 txns

Insider Ranganath Anil P.

Role See remarks

Sold 3,000 shs ($436K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,000	$0.00	--
Exercise	Common Stock	3,000	$93.88	$282K
Sale	Common Stock	3,000	$145.22	$436K

Holdings After Transaction: Stock Option (Right to Buy) — 7,420 shares (Direct); Common Stock — 16,955 shares (Direct)

Footnotes (1)

1. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $145.00 to $145.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The option vested as to 25% on June 5, 2024 and will vest as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/26/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ranganath Anil P.

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MA 01810

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		M		3,000	A	$93.88	16,955	D
Common Stock	11/25/2025		S		3,000	D	$145.22(1)	13,955	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$93.88	11/25/2025		M			3,000	(2)	08/01/2033	Common Stock	3,000	$0.00	7,420	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $145.00 to $145.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

2. The option vested as to 25% on June 5, 2024 and will vest as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.

Remarks:

Senior Vice President, General Counsel and Secretary

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.